[11C]Methionine emerges as a new biomarker for tracking active myeloma lesions.

The article discusses a prospective study which investigated the emergence of L-methyl-C methionine (MET) as a new biomarker for monitoring active myeloma lesions. Involved in the study were ten patients with biopsy-proven multiple myeloma who underwent molecular imaging using positron emission tomography (PET) with a radiolabelled glucose analogue for diagnosis. The study has shown the potential superiority of the amino acid MET for staging multiple myeloma.